RP-HPLC method for quantitative estimation of Efinaconazole in topical microemulsion and microemulsion-based-gel formulations and in presence of its degradation products
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
RP-HPLC method for quantitative estimation of Efinaconazole in topical microemulsion and microemulsion-based-gel formulations and in presence of its degradation products. / Vikas, Agrawal; Rashmin, Patel; Mrunali, Patel; Sandip, Mishra; Kaushik, Thanki.
In: Microchemical Journal, Vol. 155, 104753, 2020.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - RP-HPLC method for quantitative estimation of Efinaconazole in topical microemulsion and microemulsion-based-gel formulations and in presence of its degradation products
AU - Vikas, Agrawal
AU - Rashmin, Patel
AU - Mrunali, Patel
AU - Sandip, Mishra
AU - Kaushik, Thanki
N1 - Funding Information: The authors are grateful to MSN Laboratories Private Limited (Hyderabad, India), Abitec Corporation (Mumbai, India), Gattefosse (Mumbai, India), RAKS Pharma Pvt Ltd. (Ahmedabad, Gujarat, India) for providing support in research oriented gift samples for the present research work. Acknowledgement is also expressed towards Dr. Rahul Chavan (Scientist, NIPER, Hyderabad, India) for helping in present research work manuscript preparation. No grant was received from any of the funding agencies of public, commercial, or not-for-profit sectors for the present research work.
PY - 2020
Y1 - 2020
N2 - The aim of current research work was to establish robust, sensitive, precise and selective reversed-phase high-performance liquid chromatography (RP-HPLC) method for the quantification of efinaconazole from microemulsion and microemulsion-gel based formulations for onychomycosis treatment. Chromatographic separation of efinaconazole was performed on Waters Inertsil® HPLC column, 5 µm (ODS-3V C18, 250 × 4.6 mm). The mobile phase was optimized as mixture of X and Y components in 20:80 v/v proportion (X component contains 0.01M phosphate buffer having pH 5.5 and acetonitrile in 75:25 v/v proportion and Y component contains acetonitrile) and the flow rate optimized at 1 mL min−1. Efinaconazole detection and quantification was done at a wavelength of 210 nm using a ultra-violet (UV) detector. Linear relationship was observed in method calibration curve for the concentration range of 50–150 µg/mL with r2 value >0.99. Different stress conditions experiments were carried out for the efinaconazole method development such as in acidic, basic, oxidation, photo, thermal, and humidity condition and no unknown degradation products interference were found during the estimation of efinaconazole. Further, the matrix effect of a microemulsion based excipients like diethylene glycol monoethyl ether, caprylcaproyl macrogol glycerides, and glyceryl caprylate has been overcame by present method of analysis with no excipient's interference. The method for analysis of efinaconazole was accurate, precise with average recovery rate of 98.6–101.6% and percentage RSD for all parameters of chromatographic system were found to be not more than 2.0%. Further, the method can be rapidly and effectively applied for the quantification of efinaconazole drug content from a microemulsion and microemulsion based gel formulations. Abbreviations: AUC, area under a curve; RP-HPLC, Reversed-phase high-performance liquid chromatography; ICH, International Council for Harmonisation; LOD, limit of detection; LOQ, limit of quantification; UV, ultra-violet; RSD, relative standard deviation; N, number of theoretical plates; Smix, surfactant mixture.
AB - The aim of current research work was to establish robust, sensitive, precise and selective reversed-phase high-performance liquid chromatography (RP-HPLC) method for the quantification of efinaconazole from microemulsion and microemulsion-gel based formulations for onychomycosis treatment. Chromatographic separation of efinaconazole was performed on Waters Inertsil® HPLC column, 5 µm (ODS-3V C18, 250 × 4.6 mm). The mobile phase was optimized as mixture of X and Y components in 20:80 v/v proportion (X component contains 0.01M phosphate buffer having pH 5.5 and acetonitrile in 75:25 v/v proportion and Y component contains acetonitrile) and the flow rate optimized at 1 mL min−1. Efinaconazole detection and quantification was done at a wavelength of 210 nm using a ultra-violet (UV) detector. Linear relationship was observed in method calibration curve for the concentration range of 50–150 µg/mL with r2 value >0.99. Different stress conditions experiments were carried out for the efinaconazole method development such as in acidic, basic, oxidation, photo, thermal, and humidity condition and no unknown degradation products interference were found during the estimation of efinaconazole. Further, the matrix effect of a microemulsion based excipients like diethylene glycol monoethyl ether, caprylcaproyl macrogol glycerides, and glyceryl caprylate has been overcame by present method of analysis with no excipient's interference. The method for analysis of efinaconazole was accurate, precise with average recovery rate of 98.6–101.6% and percentage RSD for all parameters of chromatographic system were found to be not more than 2.0%. Further, the method can be rapidly and effectively applied for the quantification of efinaconazole drug content from a microemulsion and microemulsion based gel formulations. Abbreviations: AUC, area under a curve; RP-HPLC, Reversed-phase high-performance liquid chromatography; ICH, International Council for Harmonisation; LOD, limit of detection; LOQ, limit of quantification; UV, ultra-violet; RSD, relative standard deviation; N, number of theoretical plates; Smix, surfactant mixture.
KW - Efinaconazole
KW - HPLC
KW - Microemulsion
KW - Onychomycosis
KW - Validation
U2 - 10.1016/j.microc.2020.104753
DO - 10.1016/j.microc.2020.104753
M3 - Journal article
AN - SCOPUS:85080088170
VL - 155
JO - Microchemical Journal
JF - Microchemical Journal
SN - 0026-265X
M1 - 104753
ER -
ID: 282195918